Seeking Alpha

An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was...

An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was safe and effective at treating COPD. The agency's pulmonary-allergy advisory committee is still reviewing the drug and has to vote on whether the product should be marketed, but today's positive vote makes it likely the panel will vote affirmatively to support approval. Shares remain halted.
From other sites
Comments (1)
  • b.holden
    , contributor
    Comments (39) | Send Message
     
    Soon next in line
    THLD
    (I hope!)
    Lars
    17 Apr 2013, 08:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs